Patrick G Lepore
CIK 1055404 · Executive Chairman · last filed 2025-12-15
Patrick G Lepore is an Executive Chairman who has filed 79 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for VYNE, was dated Dec 15, 2025. Across all open-market trades the lifetime net is +$966.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions. 3 SEC filings were submitted jointly with Innoviva, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
FAIRLAWN, NJ 07410
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc. (VYNE) Delisted | Director | 1,029 | $28.56 | $29.4K | $399.9K | 15 | 2025-12-15 |
| LANNETT CO INC (LCI) Delisted | Director | 146,786 | $0.69 | $100.6K | $1.65M | 16 | 2022-11-14 |
| MTNB | Director | 533 | $1.66 | $885 | $345.7K | 8 | 2020-11-10 |
| PharMerica CORP (PMC) Delisted | Director | 0 | — | — | $0 | 7 | 2017-12-08 |
| INVA | Director | 58,278 | $21.05 | $1.23M | $0 | 2 | 2017-04-24 |
| PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | Chairman and CEO | 214,793 | — | — | -$1.43M | 30 | 2012-01-13 |
Recent Filings
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-15 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-16 | VYNE Therapeutics Inc. (VYNE) Delisted | Buy (P) | +15,000 | $43.8K | EDGAR |
| 2024-12-13 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-03 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-15 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-11-17 | VYNE Therapeutics Inc. (VYNE) Delisted | Buy (P) | +13,000 | $50.8K | EDGAR |
| 2023-03-22 | VYNE Therapeutics Inc. (VYNE) Delisted | Buy (P) | +20,000 | $49.7K | EDGAR |
| 2022-11-14 | LANNETT CO INC (LCI) Delisted | Buy (P) | +100,000 | $49.0K | EDGAR |
| 2022-08-12 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-17 | LANNETT CO INC (LCI) Delisted | Buy (P) | +50,000 | $27.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.